In AML, our institution is coupling a WT1 peptide-based vaccine with Treg depletion (using an anti-human CD25 antibody), and other groups are exploring similar approaches (NCT01096602; NTC01513109). The gene discussed is WT1; the disease is acute myeloid leukemia.